Cstone Pharmaceuticals Co. Ltd. released positive data from the phase III trial, Gemstone-302, of sugemalimab plus chemotherapy for the first-line treatment of patients with stage IV squamous and non-squamous non-small cell lung cancer.
Autumn's arrival in the Northern Hemisphere on Sept. 22 swept in significant news of progress for the global fight against COVID-19. A protein-based COVID-19 vaccine candidate from Clover Biopharmaceuticals Ltd. and Dynavax Technologies Corp. appeared wholly effective in preventing severe disease and hospitalization, sending Dynavax shares (NASDAQ:DVAX) climbing 26.5% to close at $18.79 on Sept. 22. In another study of Gilead Sciences Inc.'s Veklury (remdesivir), the drug significantly reduced hospitalization in high-risk patients with COVID-19. Meanwhile, governments and companies continued to expand efforts to supply new vaccines and therapeutics against the disease even as efforts continued far and wide to evaluate the efficacy of new and emerging candidates in both categories.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Clearside, Demerx, Hightide, Hoth, Hutchmed, J&J, Lyra, Moderna, Poxel, PTC, Rhovac, Small Pharma, Stoke, Vigeo, Zenith.
Despite Beyondspring Pharmaceuticals Inc.’s phase III study meeting its primary and key secondary endpoints of a plinabulin/docetaxel combination in treating non-small-cell lung cancer (NSCLC), the company stock (NADAQ:BYSI) took a pounding. Shares sunk 32.9% on Sept. 20 to close at $15.36 each.
Fresh data from Johnson & Johnson show COVID-19 protection dramatically increased with a booster shot of its single-dose vaccine, adding momentum to the U.S. drive for boosters.
Prophet, Oncohost Ltd.’s artificial intelligence-driven proteomics profiling platform, predicted response to immune checkpoint inhibitor (ICI) therapy in non-small-cell lung carcinoma (NSCLC) patients in a study presented at the European Society for Medical Oncology Virtual Congress 2021. While ICI can generate a significant positive response in some patients with advanced NSCLC, in others the therapy promotes tumor growth, making identification of likely responders prior to treatment critical.
Sanofi SA’s high-profile phase III blow-up Sept. 9 with the oral BTK inhibitor rilzabrutinib in pemphigus brought fresh attention to the group of rare diseases – which cause blisters on the skin and mucous membranes throughout the body – and to players pushing for a new treatment.
Despite Beyondspring Pharmaceuticals Inc.’s phase III study meeting its primary and key secondary endpoints of a plinabulin/docetaxel combination in treating non-small-cell lung cancer (NSCLC), the company stock (NADAQ:BYSI) took a pounding. Shares sunk 32.9% on Sept. 20 to close at $15.36 each.
RSS
